GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that compounds from its Beta-catenin pathway inhibitor program demonstrated significant tumor growth inhibition in multiple animal models. The results will be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA, from 12:30pm-2:30pm and from 5:30pm-7:30pm (PDT) in two posters titled:
